Optimising the Use of Depot Antipsychotics

Dencker, S. J.; Axelsson, Rolf

doi:10.2165/00023210-199606050-00004

Cited by 35 publications

(27 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With a depot antipsychotic, compliance to therapy can be improved. [11][12][13][14][15] Thus, a higher number of prescription gaps is what we expected in the group of new users of depot antipsychotics compared with oral antipsychotics. Interestingly, male patients are also more likely to be prescribed depot antipsychotics than female patients.…”

Section: Discussionmentioning

confidence: 99%

“…10 A depot antipsychotic aims at promoting compliance in people with particularly severe mental illnesses, thereby enhancing relapse prevention. [11][12][13][14][15][16] Several studies showed advantages of a depot regarding rates and durations of rehospitalization compared with oral antipsychotics. 11 Guidelines recommend considering depot antipsychotics in patients with repeated nonadherence.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Predictors for Starting Depot Administration of Risperidone in Chronic Users of Antipsychotics

Vehof

Postma

Bruggeman

et al. 2008

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

The results suggest that, compared with oral antipsychotics, patients receiving a depot are less compliant users, with more extrapyramidal side effects. Compared with FGA depot, patients receiving RLAI tend to be more severely ill patients. We conclude that RLAI may be partly channeled to patients as a last resort, which may have important consequences for the interpretation of observational effectiveness comparisons between RLAI and other antipsychotics in daily practice.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Predictors for Starting Depot Administration of Risperidone in Chronic Users of Antipsychotics

Vehof

Postma

Bruggeman

et al. 2008

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Prescribing practices for depot antipsychotics differ significantly between countries, with higher rates of depot prescribing in Denmark, Sweden and the UK, and lower rates in France and the USA (Dencker & Axelsson, 1996). Prescribing habits can also vary greatly within a region and between regions of one country (Taylor et al, 1999).…”

Section: Underutilisation: Clinicians' Fears and Expectationsmentioning

confidence: 99%

“…Depot medication is often regarded as useful only in those patients who are at high risk of non-adherence to treatment (Barnes & Curson, 1994;Davis et al, 1994). Some clinicians may be largely unfamiliar with current prescribing guidelines for depot antipsychotics (Kissling, 1994;Dencker & Axelsson, 1996) and therefore use inadequate doses or discontinue treatment too rapidly, or even prematurely, resulting in unfavourable outcomes in terms of relapse prevention.…”

Section: The Impact Of Prescribing Knowledge and Experiencementioning

confidence: 99%

See 1 more Smart Citation

Why aren't depot antipsychotics prescribed more often and what can be done about it?

Patel¹,

David²

2005

Adv. psychiatr. treat

105

View full text Add to dashboard Cite

show abstract

Adverse Effects Associated with Second‐Generation Antipsychotic Long‐Acting Injection Treatment: A Comprehensive Systematic Review

Gentile¹

2013

Pharmacotherapy

View full text Add to dashboard Cite

As second-generation antipsychotic long-acting injections (SGA-LAIs) are rapidly replacing depot first-generation antipsychotics as first-line agents in treating schizophrenia spectrum disorders, a systematic assessment of their adverse effects is timely. English-language, peer-reviewed articles reporting original data on the safety and tolerability of SGA-LAIs were identified electronically by searching the MEDLINE, EMBASE, PsycINFO, and DARE databases and the Cochrane Library (January 2001-April 2013). In addition to second-generation (atypical) antipsychotics and long-acting injection (depot) antipsychotics, a separate search was performed for each available drug: aripiprazole LAI, olanzapine pamoate, paliperidone palmitate, and risperidone LAI. Articles were excluded if they were review articles, post hoc analyses, analyses of subsets of patients enrolled in previous trials, single case reports, case series studies, small naturalistic studies (involving less than 50 patients), studies providing no safety data, and studies lasting less than 8 weeks. Of 181 articles identified from the search, 140 were excluded; thus, 41 articles met the inclusion criteria. Predictably, the reviewed information revealed that SGA-LAIs have safety profiles consistent with their oral parent formulations. However, they seem to also show unforeseen and worrisome safety signals. Indeed, the routine use of olanzapine-LAI in clinical practice could be limited not only by the well-known risk of postinjection syndrome, whose clinical management remains a matter of concern, but also by the risk of worsening of psychosis. The reviewed information seems to suggest that worsening of psychotic symptoms and depression could also be associated with both risperidone-LAI and paliperidone palmitate. The leading cause of death among patients enrolled in risperidone-LAI studies was suicide. Given the exponential growth in the clinical use of SGA-LAIs, further studies must be urgently performed in order to confirm or exclude the potential safety signals associated with such drugs.

show abstract

Optimising the Use of Depot Antipsychotics

Cited by 35 publications

References 56 publications

Predictors for Starting Depot Administration of Risperidone in Chronic Users of Antipsychotics

Predictors for Starting Depot Administration of Risperidone in Chronic Users of Antipsychotics

Why aren't depot antipsychotics prescribed more often and what can be done about it?

Adverse Effects Associated with Second‐Generation Antipsychotic Long‐Acting Injection Treatment: A Comprehensive Systematic Review

Contact Info

Product

Resources

About